Linked Life Data

19122034

Source:http://linkedlifedata.com/resource/pubmed/id/19122034

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-1-5
pubmed:abstractText
To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1526-632X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
6
pubmed:volume
72
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
73-9
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19122034-Administration, Oral, pubmed-meshheading:19122034-Adolescent, pubmed-meshheading:19122034-Adult, pubmed-meshheading:19122034-Disability Evaluation, pubmed-meshheading:19122034-Double-Blind Method, pubmed-meshheading:19122034-Female, pubmed-meshheading:19122034-Humans, pubmed-meshheading:19122034-Immunosuppressive Agents, pubmed-meshheading:19122034-Incidence, pubmed-meshheading:19122034-Kaplan-Meier Estimate, pubmed-meshheading:19122034-Magnetic Resonance Imaging, pubmed-meshheading:19122034-Male, pubmed-meshheading:19122034-Middle Aged, pubmed-meshheading:19122034-Multiple Sclerosis, pubmed-meshheading:19122034-Propylene Glycols, pubmed-meshheading:19122034-Respiratory Function Tests, pubmed-meshheading:19122034-Severity of Illness Index, pubmed-meshheading:19122034-Sphingosine, pubmed-meshheading:19122034-Time Factors, pubmed-meshheading:19122034-Young Adult
pubmed:year
2009
pubmed:articleTitle
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
pubmed:affiliation
St. Michael's Hospital, Toronto, ON, Canada. oconnorp@smh.toronto.on.ca
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II